Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

MorphoSys AG (0FAU)

  Print      Mail a friend       Annual reports

Thursday 25 November, 2010

MorphoSys AG

MorphoSys Presents Comprehensive Pipeline and T...




MorphoSys AG /
MorphoSys Presents Comprehensive Pipeline and Technology Update at R&D Day in 
London 
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement. 

Multiple Sclerosis Announced as Second Indication for MOR103

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will present significant
recent developments and provide a full outlook on its partnered and proprietary
drug pipeline as well as a comprehensive technology update during today's R&D
Day to be held in London starting at 9.30 am GMT. A second event will be held in
New York on November 29, 2010 starting at 11.30 am EST. MorphoSys has built one
of the broadest antibody pipelines in the biotechnology industry with 12
clinical projects ongoing and a total of 76 distinct drug programs.

Today's event will be held at Berenberg's offices at 60 Threadneedle Street,
London, EC2R 8HP, UK and can be viewed via webcast at www.morphosys.com. The New
York event will be held at The W Hotel, 541 Lexington Avenue, New York, NY
10022, USA and registration is possible at www.morphosys.com/rnd-day2010.

New Announcements at Today's R&D Day include:

  * Disclosure of multiple sclerosis as the second indication for the Company's
    lead development program MOR103, a fully human HuCAL antibody targeting GM-
    CSF. The decision is based on a compelling scientific rationale and
    promising pre-clinical data. MorphoSys expects to start a phase 1b trial in
    multiple sclerosis with MOR103 in H2 2011.
  * Preclinical data for MOR103 in both rheumatoid arthritis (RA) and multiple
    sclerosis and an update on imaging/biomarkers used in the ongoing phase
    1b/2a study in RA.
  * Preclinical data for MOR202, a HuCAL antibody targeting CD38 to treat
    multiple myeloma. A clinical trial application (CTA) to initiate a phase
    1/2a trial with MOR202 in patients with relapsed/refractory myeloma has been
    filed in Europe and the Company expects to dose the first patient in H1
    2011.
  * An update on MOR208, an Fc-enhanced anti-CD19 antibody to treat B-cell
    malignancies. The program was in-licensed from Xencor in June 2010 and is
    currently in a phase 1 clinical trial in relapsed or refractory CLL/SLL in
    the US with patient enrollment expected imminently.
  * An update on the Company's partnered pipeline, comprising now five partnered
    projects in phase 2 clinical trials. Roche has started a phase 2 clinical
    trial with Gantenerumab, a HuCAL antibody against amyloid-beta to treat
    Alzheimer's disease.
  * The latest technology developments, such as the recently announced
    optimization platform arYla(TM), as well as additional modules for more
    efficient selection and screening of antibody libraries.


"MorphoSys has established a significant proprietary product portfolio and its
clinical programs MOR103, MOR202 and MOR208 are on track to generate lucrative
out-licensing opportunities in the years ahead," commented Dr. Arndt
Schottelius, Chief Development Officer of MorphoSys. "Our decision to develop
MOR103 in a second indication beyond rheumatoid arthritis, namely multiple
sclerosis, is based on a compelling scientific rationale and promising pre-
clinical data and we are intrigued by its prospects. I'm excited about the
progress we've made in Proprietary Development since I joined MorphoSys two
years ago."


"The commercial opportunity for therapeutic antibodies is enormous. As we learn
more about this class of drugs we are identifying ways of making antibodies that
will be superior to currently available drugs, and our strategy is to command
and apply a range of technologies to deliver these new therapies." commented Dr.
Marlies Sproll, Chief Scientific Officer of MorphoSys. "MorphoSys has now
established a suite of technologies to enable generation of the best possible
therapeutic antibodies and continues to set industry standards with its new
arYla(TM) antibody optimization technology."



MorphoSys will hold a public conference call today at 09:30 GMT (10:30 CET) to
give an update on its partnered pipeline, proprietary portfolio and recent
technology developments.


Dial-in number for the Conference Call (listen-only):


Germany: +49 (0) 89 24443 2975
For U.K. residents: +44 (0) 20 3003 2666
For U.S. residents: +1 212 999 6659

Please dial in 10 minutes before the beginning of the conference.
In addition, MorphoSys offers participants the opportunity to follow the
presentation through a simultaneous slide presentation online
at

http://www.morphosys.com.


A live webcast, slides, webcast replay and transcript will be made available
at 

http://www.morphosys.com.

About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visit

http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered
trademarks of MorphoSys. arYla(TM) is a trademark of MorphoSys.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.

 
For more information, please contact:
MorphoSys AG


Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

[email protected]



[HUG#1465353]



 --- End of Message --- 

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Press Release (PDF): 


http://hugin.info/130295/R/1465353/403558.pdf




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: MorphoSys AG via Thomson Reuters ONE
  



                                                                                                                                                                            

a d v e r t i s e m e n t